A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration

This is a 52-week, multicenter, open label trial of memantine (Namenda) for frontotemporal lobar degeneration (FTLD). The goal is to determine the safety and tolerability of this FDA-approved medication for Alzheimer's Disease in patients with FTLD. Secondary outcome measures include cognitive batteries, rating scales for activities of daily living and neuropsychiatric symptoms. All patients receive the FDA-approved dose of this medication for Alzheimer's disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Frontotemporal Lobar Degeneration Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Metabolic Diseases Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Nutritional and Metabolic Diseases Proteostasis Deficiencies TDP-43 Proteinopathies

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Neary et al. Criteria for Frontotemporal Lobar Degeneration
Age 40 -80
CDR < 3 or MMSE > 15
English Speaking
Study Partner

Exclusion criteria

Concurrent use of antipsychotic drugs or acetylcholinesterase inhibitors

Treatment and study plan

Memantine

Drug

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Collaborators

Forest Laboratories

Registry information

Important dates

Study start: 2004
Primary completion: 2005
Study completion: 2006
First posted: Sep 16, 2005
Registry last updated: Nov 12, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed